Cell surface tropomyosin as a target of angiogenesis inhibition
CA 2478962 A1 · Owner: Mccrae, Keith · Inventors: Mccrae, Keith; Donate, Fernando; Juarez, Jose
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to novel methods for inhibiting angiogenesis and treating tumors and cancer by targeting tropomyosin (Tpm) expressed on the surface of endothelial cells and/or tumor cells to Tpm polypeptides and , peptides, as well as variants and derivatives thereof that bind inhibitors of angiogenesis, and to anti-Tpm antibodies that block or stimulate angiogenesis. Cyclic peptides that bind to the D5 subunit of HKa and inhibit angiogenesis are also included. Method for screening test compounds as candidate antiangiogenic molecule that binds to Tpm are disclosed as are affinity , ligands comprising the proteins peptides, variants and derivatives of the invention.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 17, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 17, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 17, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.